A Review on the Relationship between Aspirin and Bone Health

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aspirin is a cyclooxygenase inhibitor commonly used in primary prevention of cardiovascular diseases and cancers. Its users are elderly population susceptible to osteoporosis. It also inhibits the synthesis of prostaglandin E2 essential in bone remodeling. This prompts the question whether it can influence bone health among users. This review aimed to summarize the current literature on the use of aspirin on bone health. A literature search on experimental and clinical evidence on the effects of aspirin on bone health was performed using major scientific databases. In vitro studies showed that aspirin could enhance the survival of bone marrow mesenchymal stem cells, the progenitors of osteoblasts, and stimulate the differentiation of preosteoblasts. Aspirin also inhibited the nuclear factor kappa-B (NFB) pathway and decreased the expression of receptor activator of NFB ligand, thus suppressing the formation of osteoclast. Aspirin could prevent bone loss in animal models of osteoporosis. Despite a positive effect on bone mineral density, the limited human epidemiological studies revealed that aspirin could not reduce fracture risk. A study even suggested that the use of aspirin increased fracture risk. As a conclusion, aspirin may increase bone mineral density but its effect on fracture prevention is inconclusive. More data are needed to determine the effects of aspirin and bone health in human.

Original languageEnglish
Article number3710959
JournalJournal of Osteoporosis
Volume2017
DOIs
Publication statusPublished - 2017

Fingerprint

Aspirin
Bone and Bones
Health
Bone Density
Osteoporosis
RANK Ligand
Cyclooxygenase Inhibitors
NF-kappa B
Bone Remodeling
Osteoclasts
Primary Prevention
Osteoblasts
Mesenchymal Stromal Cells
Dinoprostone
Epidemiologic Studies
Cardiovascular Diseases
Animal Models
Bone Marrow
Databases
Population

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

A Review on the Relationship between Aspirin and Bone Health. / Kok Yong, Chin.

In: Journal of Osteoporosis, Vol. 2017, 3710959, 2017.

Research output: Contribution to journalArticle

@article{f4186405b34240bd92f0569d258a8912,
title = "A Review on the Relationship between Aspirin and Bone Health",
abstract = "Aspirin is a cyclooxygenase inhibitor commonly used in primary prevention of cardiovascular diseases and cancers. Its users are elderly population susceptible to osteoporosis. It also inhibits the synthesis of prostaglandin E2 essential in bone remodeling. This prompts the question whether it can influence bone health among users. This review aimed to summarize the current literature on the use of aspirin on bone health. A literature search on experimental and clinical evidence on the effects of aspirin on bone health was performed using major scientific databases. In vitro studies showed that aspirin could enhance the survival of bone marrow mesenchymal stem cells, the progenitors of osteoblasts, and stimulate the differentiation of preosteoblasts. Aspirin also inhibited the nuclear factor kappa-B (NFB) pathway and decreased the expression of receptor activator of NFB ligand, thus suppressing the formation of osteoclast. Aspirin could prevent bone loss in animal models of osteoporosis. Despite a positive effect on bone mineral density, the limited human epidemiological studies revealed that aspirin could not reduce fracture risk. A study even suggested that the use of aspirin increased fracture risk. As a conclusion, aspirin may increase bone mineral density but its effect on fracture prevention is inconclusive. More data are needed to determine the effects of aspirin and bone health in human.",
author = "{Kok Yong}, Chin",
year = "2017",
doi = "10.1155/2017/3710959",
language = "English",
volume = "2017",
journal = "Journal of Osteoporosis",
issn = "2090-8059",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - A Review on the Relationship between Aspirin and Bone Health

AU - Kok Yong, Chin

PY - 2017

Y1 - 2017

N2 - Aspirin is a cyclooxygenase inhibitor commonly used in primary prevention of cardiovascular diseases and cancers. Its users are elderly population susceptible to osteoporosis. It also inhibits the synthesis of prostaglandin E2 essential in bone remodeling. This prompts the question whether it can influence bone health among users. This review aimed to summarize the current literature on the use of aspirin on bone health. A literature search on experimental and clinical evidence on the effects of aspirin on bone health was performed using major scientific databases. In vitro studies showed that aspirin could enhance the survival of bone marrow mesenchymal stem cells, the progenitors of osteoblasts, and stimulate the differentiation of preosteoblasts. Aspirin also inhibited the nuclear factor kappa-B (NFB) pathway and decreased the expression of receptor activator of NFB ligand, thus suppressing the formation of osteoclast. Aspirin could prevent bone loss in animal models of osteoporosis. Despite a positive effect on bone mineral density, the limited human epidemiological studies revealed that aspirin could not reduce fracture risk. A study even suggested that the use of aspirin increased fracture risk. As a conclusion, aspirin may increase bone mineral density but its effect on fracture prevention is inconclusive. More data are needed to determine the effects of aspirin and bone health in human.

AB - Aspirin is a cyclooxygenase inhibitor commonly used in primary prevention of cardiovascular diseases and cancers. Its users are elderly population susceptible to osteoporosis. It also inhibits the synthesis of prostaglandin E2 essential in bone remodeling. This prompts the question whether it can influence bone health among users. This review aimed to summarize the current literature on the use of aspirin on bone health. A literature search on experimental and clinical evidence on the effects of aspirin on bone health was performed using major scientific databases. In vitro studies showed that aspirin could enhance the survival of bone marrow mesenchymal stem cells, the progenitors of osteoblasts, and stimulate the differentiation of preosteoblasts. Aspirin also inhibited the nuclear factor kappa-B (NFB) pathway and decreased the expression of receptor activator of NFB ligand, thus suppressing the formation of osteoclast. Aspirin could prevent bone loss in animal models of osteoporosis. Despite a positive effect on bone mineral density, the limited human epidemiological studies revealed that aspirin could not reduce fracture risk. A study even suggested that the use of aspirin increased fracture risk. As a conclusion, aspirin may increase bone mineral density but its effect on fracture prevention is inconclusive. More data are needed to determine the effects of aspirin and bone health in human.

UR - http://www.scopus.com/inward/record.url?scp=85010677259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010677259&partnerID=8YFLogxK

U2 - 10.1155/2017/3710959

DO - 10.1155/2017/3710959

M3 - Article

VL - 2017

JO - Journal of Osteoporosis

JF - Journal of Osteoporosis

SN - 2090-8059

M1 - 3710959

ER -